David Garza, OD
Optometrist · Houston, TXNPI 1194721423
Payments from drug & device makers
Across 194 payments — averaging $56.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coopervision Inc.$6K
- Alcon$1K
- AbbVie$929
- Glaukos Corporation$619
- Bausch & Lomb Americas Inc.$605
- Johnson & Johnson Vision Care, Inc.$393
- plus $1K from 18 others
What the payments were for
- Speaking & faculty fees$5,37549%
- Food & beverage$5,63051%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coopervision Inc. | 16 | $5,901 |
| Alcon | 34 | $1,058 |
| AbbVie(2 entities) | 42 | $929 |
| Glaukos Corporation | 6 | $619 |
| Bausch & Lomb Americas Inc. | 23 | $605 |
| Johnson & Johnson Vision Care, Inc. | 11 | $393 |
| Tarsus Pharmaceuticals, Inc. | 10 | $285 |
| Rxsight Inc | 4 | $182 |
| Sun Pharmaceutical Industries Inc. | 8 | $168 |
| Dompe US, Inc. | 5 | $141 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $123 |
| Novartis | 5 | $119 |
| Oyster Point Pharma, Inc. | 5 | $101 |
| Biotissue Holdings Inc. | 4 | $76 |
| Harrow Eye, LLC | 3 | $69 |
| Aerie Pharmaceuticals, Inc. | 2 | $53 |
| Astellas Pharma US Inc | 2 | $47 |
| Axsome Therapeutics, Inc. | 1 | $29 |
| Shire North American Group Inc | 2 | $24 |
| Carl Zeiss Meditec USA, Inc. | 1 | $19 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $18 |
| Sight Sciences, Inc. | 1 | $16 |
| Eyepoint US, Inc. | 1 | $14 |
| Eyevance Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Clariti Contact Lens$3,500
- MiSight Contact Lens$1,992
- TOTAL30$297
- iDose$243
- INFUSE$230
- AcrySof IQ PanOptix$143
- VUITY$138
- IACCESS$132
- iStent inject W$132
- RXSIGHT CONTACT LENS$129
- RXSIGHT INJECTOR CARTRIDGE$129
- RXSIGHT INJECTOR HANDPIECE$129
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$129
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$129
- Acuvue$123
- iStent infinite Trabecular Micro-Bypass System Model iS3$112
- AIR OPTIX$109
- iDoseTR$106
- iStent Infinite$106
How this compares
$11,005 in reported general payments places this provider in the 95th percentile of 4,315 optometrist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 144 | $76,827 |
| XdemvyLotilaner | 26 | $46,476 |
| TyrvayaVarenicline Tartrate | 36 | $39,644 |
| RestasisCyclosporine | 23 | $31,815 |
| XiidraLifitegrast | 14 | $24,909 |
| RocklatanNetarsudil Mesylat/Latanoprost | 22 | $16,330 |
| CombiganBrimonidine Tartrate/Timolol | 39 | $13,708 |
| Latanoprost | 717 | $10,615 |
| Cyclosporine | 12 | $8,833 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 36 | $8,162 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 24 | $7,725 |
| Epinastine Hcl | 94 | $6,827 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 206 | $4,782 |
| Brinzolamide | 15 | $4,153 |
| Bromfenac Sodium | 21 | $3,413 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan | $929 | $122,351206 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $285 | $46,47626 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $101 | $39,64436 claims |
| Bausch & Lomb Americas Inc.Xiidra | $605 | $24,90914 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $53 | $16,33022 claims |
| AlconSimbrinza | $1,058 | $7,72524 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,315 optometrist providers in Texas.
Other optometrist in Houston
- Tiffany HuynhHouston$3.2M
- Bridgitte LeeHouston$3M
- Phillip BrunsonHouston$766K
- Claudio LagunasHouston$644K
- Ashley Wallace-TuckerHouston$568K
- Kathryn RichdaleHouston$288K
- Nancy StephensHouston$241K
- Jelita Green-DathorneHouston$232K
- Eric RitcheyHouston$151K
- Maria WalkerHouston$128K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.